The CONSORT Group met in Montebello, Canada in January 2007; the participants were 28 invited investigators, journal editors and other experts from around the world. The aims of the three-day meeting were to revise the 2001 CONSORT Statement, to develop a CONSORT extension for trials reported in journal and conference abstracts, and to discuss more general CONSORT issues.
Based on the emerging evidence that was presented, a number of modifications to the CONSORT checklist and Explanation and Elaboration document (E&E) were deliberated. On the agenda were the reporting of trial registration, stopping issues, role of funders, testing of blinding, surrogate outcomes, composite outcomes, selective outcomes, and attrition. The Group will be working on the third version of the CONSORT Statement and a revision of the accompanying E&E in the coming months.
One day of the meeting was devoted to developing an extension to the CONSORT Statement specifically for trials reported in conference and journal abstracts. Research on abstracts was presented, demonstrating the need for guidelines on reporting results of randomized trials in journal and in conference abstracts. The Group then provided input on the initial development of a CONSORT for Abstracts checklist. Publication of this new extension is likely to occur later this year.
The current position and future of CONSORT was discussed with respect to funding, implementation and dissemination. The redesigning of the CONSORT website and the EQUATOR network were introduced to the Group. Many useful ideas were given about dealing with challenges and considering new technologies and resources.
We are grateful to all the supporters of the meeting: UK National Co-ordinating Centre for Research Methodology, Cancer Research UK,Family Health International, University of Ottawa, American Society of Clinical Oncology, Canadian Institutes of Health Research, Johnson & Johnson, BMJ, UK Cochrane Centre, Nordic Cochrane Centre, andThe Lancet.